Vascular Biology in Clinical Practice © Vol. 7, No. 1
• ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection
This monograph, ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection
, which is being offered as part of a series of continuing medical education activities from the University of Florida College of Medicine. Co-editors are Carl J. Pepine, MD, University of Florida College of Medicine, and Willem J. Remme, MD, PhD, Carol Davila University.
The monograph discusses the role of angiotensin II in the development of coronary artery disease (CAD) and the rationale for angiotensin-converting enzyme (ACE) inhibition to reduce the risk of major adverse cardiac events in patients with the disease. Importantly, the contents highlight the results of major clinical trials, including HOPE and the more recent EUROPA study, which extended the benefits of ACE inhibition to nearly all patients with stable coronary artery disease and without heart failure or left ventricular dysfunction. Results of these studies show consistent benefits of ACE inhibition in patients at all levels of risk and in addition to other state-of-the-art therapy. EUROPA showed benefits in patients age 18 years and older, while the HOPE study showed benefits in patients who were age 55 years and older. The importance of considering clinical trial evidence when choosing an agent and dose is also discussed.
The editorial contents of this monograph express the views of the
individual contributors and do not necessarily reflect the views or
recommendations of the University of Florida College of Medicine,
Carol Davila University, Sticares Cardiovascular Research Institute,
CV Therapeutics Inc, or the publisher. The reader is advised to consult
the full prescribing information for all medications prior to use.
Supported by an educational grant from CV Therapeutics, Inc.
© 2005 Medical Education Consultants, LLCSM(MEDCON).
All rights reserved.